Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 68

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 68
---
5202420252024(unaudited)(unaudited)RevenuesNet product sales$157,995 $162,538 $299,983 $300,999 Royalty, licensing and other revenues7,458 5,787 15,294 10,970 Total revenues165,453 168,325 315,277 311,969 Costs and expensesCost of goods sold(a)16,827 17,916 32,590 34,225 Research and development22,115 26,183 49,042 51,113 Selling, general and administrative93,551 85,904 183,495 172,420 Amortization of intangible assets20,819 20,108 40,605 40,245 Contingent consideration loss (gain)— (4,355)7,660 (5,450)Total costs and expenses153,312 145,756 313,392 292,553 Operating earnings12,141 22,569 1,885 19,416 Other income (expense)Interest and other income, net4,528 3,733 8,953 7,129 Total other income (expense), net4,528 3,733 8,953 7,129 Earnings before income taxes16,669 26,302 10,838 26,545 Income tax expense (benefit)(5,830)6,386 166 6,505 Net earnings$22,499 $19,916 $10,672 $20,040 Earnings per shareBasic$0.40 $0.36 $0.19 $0.37 Diluted$0.40 $0.36 $0.19 $0.36 Weighted average shares outstandingBasic56,024,771 54,978,781 55,945,434 54,890,265 Diluted56,643,189 55,724,283 56,688,754 55,675,474 _____________________________

(a) Excludes amortization of acquired intangible assets

See accompanying notes.

4

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Earnings

(in thousands)

Three Months EndedJune 30,Six Months EndedJune 30,202520242